OncoGenex has announced plans to begin a Phase II trial of OGX-427 in treatment-naive metastatic pancreatic cancer patients.

OGX-427 in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) and gemcitabine will be studied in the randomised, placebo-controlled trial, named Rainier.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The University of California, San Francisco, haematology / oncology division associate professor of medicine and trial primary investigator Dr Andrew Ko said that while previous trial results suggest patients with advanced pancreatic cancer are likely to receive treatment with gemcitabine plus Abraxane in the future, there is a need to improve survival times for these patients.

"OGX-427 in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) and gemcitabine will be studied in the randomised, placebo-controlled trial."

"The Rainier trial provides us the opportunity to explore the role of Hsp27 in pancreatic cancer, and the potential ability of OGX-427 to improve on clinical outcomes when added to combination chemotherapy," Ko said.

Around 130 patients are expected to be randomised with either OGX-427 or placebo in combination with Abraxane and gemcitabine therapy.

See Also:

Overall survival is the primary endpoint of the trial, which will also assess progression-free survival (PFS), tumour response rates, safety, tolerability and the effect of therapy on heat shock protein (Hsp27) levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Sarah Cannon Research Institute (SCRI) is sponsoring the trial, which will be conducted at around 12 sites across the US.

SCRI GI Cancer Research Programme director Dr Johanna Bendell said; "We are very excited to bring this trial of an exciting novel agent to patients with metastatic pancreatic cancer, who desperately need more treatment options."